CR6505A - Compuestos de benzolactama sustituidos - Google Patents

Compuestos de benzolactama sustituidos

Info

Publication number
CR6505A
CR6505A CR6505A CR6505A CR6505A CR 6505 A CR6505 A CR 6505A CR 6505 A CR6505 A CR 6505A CR 6505 A CR6505 A CR 6505A CR 6505 A CR6505 A CR 6505A
Authority
CR
Costa Rica
Prior art keywords
substituted
compounds
benzolactama
specialists
chemotherapy
Prior art date
Application number
CR6505A
Other languages
English (en)
Inventor
Bweth Sobolov-Jaynes Susan
Original Assignee
Pfizer Prod Inc
Abr Llc
Acumer Investigacion Desarrollo S L
Antonio Jose De Jesus De San Juan Bosco Echevarria Parres
Dystar Textilfarben Gmbh Y Co Deutschland Kg
Eco Flora S A
John Larry Sanders
Ranka Seema Ajay
Sanofi Aventis
Smithjkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Abr Llc, Acumer Investigacion Desarrollo S L, Antonio Jose De Jesus De San Juan Bosco Echevarria Parres, Dystar Textilfarben Gmbh Y Co Deutschland Kg, Eco Flora S A, John Larry Sanders, Ranka Seema Ajay, Sanofi Aventis, Smithjkline Beecham Corp filed Critical Pfizer Prod Inc
Publication of CR6505A publication Critical patent/CR6505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

Se refiere a compuestos de benzolactama y tioamida cíclica, sustituidos, de interés para los especialistas del campo de la química médica y la quimioterapia.
CR6505A 1999-05-06 2001-11-19 Compuestos de benzolactama sustituidos CR6505A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13285899P 1999-05-06 1999-05-06

Publications (1)

Publication Number Publication Date
CR6505A true CR6505A (es) 2004-03-24

Family

ID=22455915

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6505A CR6505A (es) 1999-05-06 2001-11-19 Compuestos de benzolactama sustituidos

Country Status (40)

Country Link
EP (1) EP1175417B1 (es)
JP (1) JP2002544128A (es)
KR (1) KR20020015319A (es)
CN (1) CN1349527A (es)
AP (1) AP2001002314A0 (es)
AR (1) AR036320A1 (es)
AT (1) ATE257478T1 (es)
AU (1) AU3572800A (es)
BG (1) BG106141A (es)
BR (1) BR0010673A (es)
CA (1) CA2373079A1 (es)
CR (1) CR6505A (es)
CZ (1) CZ20013977A3 (es)
DE (1) DE60007625T2 (es)
DK (1) DK1175417T3 (es)
DZ (1) DZ3040A1 (es)
EA (1) EA200101050A1 (es)
EE (1) EE200100586A (es)
ES (1) ES2211520T3 (es)
GE (1) GEP20043224B (es)
GT (1) GT200000063A (es)
HK (1) HK1046144A1 (es)
HR (1) HRP20010821A2 (es)
HU (1) HUP0201135A3 (es)
IL (1) IL145945A0 (es)
IS (1) IS6122A (es)
MA (1) MA26731A1 (es)
MY (1) MY133207A (es)
NO (1) NO20015395L (es)
NZ (1) NZ514697A (es)
OA (1) OA11864A (es)
PA (1) PA8494901A1 (es)
PE (1) PE20010119A1 (es)
PL (1) PL351919A1 (es)
PT (1) PT1175417E (es)
TN (1) TNSN00095A1 (es)
TR (1) TR200103222T2 (es)
UY (1) UY26135A1 (es)
WO (1) WO2000068224A1 (es)
ZA (1) ZA200109116B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108982D0 (en) 2001-04-10 2001-05-30 Merck Sharp & Dohme Therapeutic agents
JPWO2003055858A1 (ja) * 2001-12-27 2005-05-12 東レ・ファインケミカル株式会社 １−アルコキシカルボニル含窒素飽和複素環誘導体の製造法
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2009109001A1 (en) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function
JP6156074B2 (ja) * 2013-11-08 2017-07-05 住友化学株式会社 スクシンイミド化合物及びその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
ATE199552T1 (de) * 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists

Also Published As

Publication number Publication date
HUP0201135A2 (en) 2002-09-28
BG106141A (bg) 2002-07-31
UY26135A1 (es) 2000-12-29
HUP0201135A3 (en) 2003-05-28
WO2000068224A1 (en) 2000-11-16
PL351919A1 (en) 2003-06-30
BR0010673A (pt) 2002-02-19
EE200100586A (et) 2003-02-17
IS6122A (is) 2001-10-23
NZ514697A (en) 2004-04-30
EP1175417B1 (en) 2004-01-07
DE60007625T2 (de) 2004-11-18
JP2002544128A (ja) 2002-12-24
CZ20013977A3 (cs) 2003-10-15
GEP20043224B (en) 2004-04-26
ES2211520T3 (es) 2004-07-16
HRP20010821A2 (en) 2002-12-31
EP1175417A1 (en) 2002-01-30
CA2373079A1 (en) 2000-11-16
PA8494901A1 (es) 2003-12-10
KR20020015319A (ko) 2002-02-27
GT200000063A (es) 2001-10-27
NO20015395L (no) 2001-12-11
PE20010119A1 (es) 2001-02-06
CN1349527A (zh) 2002-05-15
IL145945A0 (en) 2002-07-25
HK1046144A1 (zh) 2002-12-27
TR200103222T2 (tr) 2002-03-21
OA11864A (en) 2006-03-03
MA26731A1 (fr) 2004-12-20
EA200101050A1 (ru) 2002-04-25
NO20015395D0 (no) 2001-11-05
PT1175417E (pt) 2004-04-30
AP2001002314A0 (en) 2001-12-31
AR036320A1 (es) 2004-09-01
DK1175417T3 (da) 2004-04-05
TNSN00095A1 (fr) 2005-11-10
MY133207A (en) 2007-10-31
ATE257478T1 (de) 2004-01-15
ZA200109116B (en) 2002-11-05
DE60007625D1 (de) 2004-02-12
DZ3040A1 (fr) 2004-03-27
AU3572800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
NO20024395D0 (no) N¶ring for diabetikere
DK1487763T3 (da) Anvendelse af mikrofremstillede indretninger til radiosyntese
PT1109812E (pt) Pirrolobenzodiazepinas
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
CR7820A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
NO20031648D0 (no) Farmasöytiske lösninger av modafinilforbindelser
PA8577601A1 (es) Derivados aldehido de polietilenglicol
ECSP034754A (es) Derivados de beta-carbolina y su uso farmaceutico contra depresion y ansiedad
CR6505A (es) Compuestos de benzolactama sustituidos
SE9801494D0 (sv) Novel use
EA200100852A1 (ru) Производные резорцина
DE502004012262D1 (de) Wanderfeldmaschine
EA200401331A1 (ru) Фармацевтическая препаративная форма, включающая мелатонин
ITRM20030355A0 (it) Composti ad attivita' citotossica derivati della combretastatina.
RU2002107079A (ru) Вещество, обладающее седативным действием
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
ITMI20020597A1 (it) Derivati del probucolo
BR0316544A (pt) Compostos calcilìticos
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
ITRM20020357A0 (it) Composizione liquida per la somministrazione orale di lorazepam.
AR026423A1 (es) Derivados de bencimidazol sustituidos con carboxamida, su preparacion y su empleo como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)